This is a Phase 2 randomized, multicenter, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy of HT-0712 in improving memory and cognitive performance in subjects with Age-Associated Memory Impairment (AAMI)

Main Inclusion Criteria:

• Complaints of memory loss in everyday life
• Performance at least one standard deviation below the mean established for young adults on standardized memory tests
• Absence of dementia
• Intact global intellectual function

Main Exclusion Criteria:

• Diagnosis of Mild Cognitive Impairment (MCI) or Alzheimer's Disease
• Evidence of dementia
• Evidence of psychiatric or neurological disorder that could influence cognition or contributed to the subject's memory loss
• Use of any drugs that could influence cognition